CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.
Commentary|Podcasts|December 12, 2024
Managed Care Cast Presents: Navigating Burdens and Treatment Challenges of IPF
A trio of experts discuss the importance of early diagnosis, treatment barriers, and therapies in the pipeline for idiopathic pulmonary fibrosis (IPF).
Advertisement
Today we are bringing you insights from 3 separate interviews with experts about the treatment, management, and burdens of idiopathic pulmonary fibrosis (IPF).
In this podcast, you’ll hear insight from the following individuals:
- Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine, University of Southern California
- Martin Kolb, MD, PhD, professor of medicine, McMaster University
- Steven Nathan, MD, FCCP, medical director of the Advanced Lung Disease Program and Lung Transplant Program, Inova Fairfax Hospital, and professor of medicine, University of Virginia
These experts discuss what IPF is, how it impacts patients’ quality of life, barriers to care, and treatments in the pipeline.
Listen above or through one of these podcast services:
Advertisement
Related to this article
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.
Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.
Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.
Advertisement
Advertisement
Trending on AJMC
1
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
2
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5